Adicet bio announces poster presentation of adi-270 preclinical data at the 2024 european hematology association (eha) hybrid congress

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today announced the acceptance of a poster presentation at the upcoming european hematology association (eha) hybrid congress being held in madrid, spain from june 13-16, 2024. details of the poster presentation are as follows: title: adi-270: an armored allogeneic anti-cd70.
ACET Ratings Summary
ACET Quant Ranking